Jiangsu Anbison Pharmaceutical Co., Ltd.

FDA inspection history in Taizhou, China, 2023 to 2024

2
Form 483s

Every document, by year

  • Form 483

2023: one Form 483; 2024: one Form 483.

The story so far

Built from the dates and citations on the documents themselves.

  1. 2023–24Two Form 483s, at Taizhou, China.
  2. 2024The longest 483 on file: 3 observations over 2 pages at Taizhou, China.

Cited most

Across all Jiangsu Anbison Pharmaceutical Co. observations on file

The complete Jiangsu Anbison Pharmaceutical Co. file.

All 2 documents as original PDFs, in one order. For supplier audits, diligence and inspection prep.

$198

The price of the documents, added to your cart together

Sites

Documents

2 on file, newest first
DateDocumentPrice
2024-07-16483 Form 483$99
2023-08-18483 Form 483$99

Investigators on these documents

Patty P. Kaewussdangkul (1)

FEI number 3021121841 · most recent document Jul 16, 2024

About Jiangsu Anbison Pharmaceutical Co., Ltd.

How many FDA Form 483s has Jiangsu Anbison Pharmaceutical Co., Ltd. received?

FDA Intel has 2 Form 483s on file for Jiangsu Anbison Pharmaceutical Co., Ltd.; the most recent is dated Jul 16, 2024.

When was Jiangsu Anbison Pharmaceutical Co., Ltd. last inspected by FDA?

The most recent FDA inspection document on file for Jiangsu Anbison Pharmaceutical Co., Ltd. is a Form 483 dated Jul 16, 2024, for the site in Taizhou, China.

What did FDA cite at Jiangsu Anbison Pharmaceutical Co., Ltd.?

The regulations cited most in the observations on file for Jiangsu Anbison Pharmaceutical Co., Ltd. are 21 CFR 211.113 (Control of microbiological contamination), 1 time; 21 CFR 211.22 (Responsibilities of quality control unit), 1 time; 21 CFR 211.42 (Design and construction features), 1 time.